Skip to main content

Search

Reset all filters
520 Result(s)
Sort by

Investment of 65 million euro in avian vaccines in France

Investment of 65 million euro in avian vaccines in France

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Our evolved employer value proposition

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Transforming Science Day

Transforming Science Day

How our ‘patient first’ approach to innovation is aiming to accelerate breakthrough therapies that transform lives. Join our Transforming Science Day.
Moving to Germany

Moving to Germany

We started in Germany, but we have offices all over the world.
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Grow Your Skills

Grow Your Skills

Great things in business are never done by one person; they’re done by a team of people
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
Tomorrow's leaders

Tomorrow's leaders

We invest in our employees by giving them leadership training that enhances their skills and prepares them for future roles within the organization.